Bruno Stankoff
Overview
Explore the profile of Bruno Stankoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
2870
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ricigliano V, Marenna S, Borrelli S, Camera V, Carnero Contentti E, Szejko N, et al.
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002770
Multiple sclerosis (MS) pathology is characterized by acute and chronic inflammation, demyelination, axonal injury, and neurodegeneration. After decades of research into MS-related degeneration, recent efforts have shifted toward recovery and...
2.
Mainguy M, Casey R, Vukusic S, Lebrun-Frenay C, Berger E, Kerbrat A, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Feb;
12(2):e200371.
PMID: 39933125
Background And Objectives: Older studies reported an increased risk of relapse after in vitro fertilization (IVF) in women with multiple sclerosis (MS), which has not been confirmed by more recent...
3.
Maillart E, Dubessy A, Shor N, Piljan M, Decombe R, Lubetzki C, et al.
Neurology
. 2025 Feb;
104(5):e213399.
PMID: 39913883
Objectives: Several treatments have been approved for the prevention of attacks in AQP4-IgG+ neuromyelitis optica spectrum disorder (NMOSD). However, because of the rarity of the disease, little is known concerning...
4.
Muraro P, Mariottini A, Greco R, Burman J, Iacobaeus E, Inglese M, et al.
Nat Rev Neurol
. 2025 Jan;
21(3):140-158.
PMID: 39814869
Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for relapsing forms of multiple sclerosis (MS) that are refractory to disease-modifying therapy (DMT). AHSCT after failure of high-efficacy DMT...
5.
Androdias G, Lunemann J, Maillart E, Amato M, Audoin B, Bruijstens A, et al.
Brain
. 2024 Dec;
PMID: 39707906
The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs...
6.
Brownlee W, Vidal-Jordana A, Shatila M, Strijbis E, Schoof L, Killestein J, et al.
Ann Neurol
. 2024 Nov;
97(3):571-582.
PMID: 39605172
Objective: The 2017 McDonald criteria continued the separation of diagnostic criteria for relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) for historical, rather than biological, reasons. We aimed to...
7.
Gaubert M, Combes B, Bannier E, Masson A, Caron V, Baudron G, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Nov;
12(1):e200333.
PMID: 39571137
Background And Objectives: The dynamics of microstructural spinal cord (SC) damage and repair in people with multiple sclerosis (pwMS) and their clinical relevance have yet to be explored. We set...
8.
Fransson J, Bachelin C, Ichou F, Guillot-Noel L, Ponnaiah M, Gloaguen A, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Oct;
11(6):e200312.
PMID: 39467238
Background And Objectives: In multiple sclerosis (MS), immune cells invade the CNS and destroy myelin. Macrophages contribute to demyelination and myelin repair, and their role in each process depends on...
9.
Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G, et al.
Neurology
. 2024 Sep;
103(8):e209886.
PMID: 39321406
Background And Objectives: Although rituximab failed to demonstrate a significant effect on disability progression in primary progressive multiple sclerosis (PPMS), ocrelizumab succeeded. Our main objective was to analyze confirmed disability...
10.
Comi G, Dalla Costa G, Stankoff B, Hartung H, Soelberg Sorensen P, Vermersch P, et al.
Nat Rev Neurol
. 2024 Sep;
20(10):573-586.
PMID: 39251843
Progressive multiple sclerosis poses a considerable challenge in the evaluation of disease progression and treatment response owing to its multifaceted pathophysiology. Traditional clinical measures such as the Expanded Disability Status...